ACE2 and viral infectious disease: As illustrated in Fig 4, the incubation of ACE2-hFcLALA with the SARS-CoV-2 strongly protected VeroE6 cells from viral infection (IC50 of 21.8μg/mL, 99.6 nM), as assessment of cell viability (Fig 4B).